Suppliers / TIEN (Tianjin) Pharmaceutical

TIEN (Tianjin) Pharmaceutical

China Updated 9 July 2026

TIEN (Tianjin) Pharmaceutical is an API manufacturer based in China. It holds 5 active US drug master files across a filed portfolio of 4 molecules. Its most recent recorded inspection, by US FDA, closed on 7 July 2017 as NAI.

5
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 7 July 2017 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3010666505

What they file, and where

Molecule Regulators Docs
Treprostinil US FDA 2
Alprostadil US FDA 1
Carboprost US FDA 1
Dinoprostone US FDA 1

Also appears on these molecule pages

Alprostadil API Carboprost API Treprostinil API

Comparing suppliers?

Choose your molecules and target markets. TIEN (Tianjin) Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 7 July 2017.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability